Could a gut bacteria byproduct tame MS?

NCT ID NCT07318129

Recruiting now Disease control Sponsor: Glostrup University Hospital, Copenhagen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether a daily supplement of indole-3-propionic acid (IPA), a substance naturally made by gut bacteria, can help people with relapsing-remitting multiple sclerosis (RRMS). Over 27 months, 220 adults will take either IPA or a placebo. The main goal is to see if IPA reduces disease activity, including relapses, brain lesions, and disability progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indole-3-propionic acid (IPA), a natural gut bacteria byproduct, taken as a daily supplement
What this could lead to: If it works, this could point toward a simple dietary supplement that helps control MS disease activity and slow neurodegeneration.
What could go wrong: This is an early-stage trial with no phase designation, so results are uncertain. The supplement may not outperform placebo, and benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)

Contacts and locations

Locations

Glostrup Hospital
RECRUITING

Glostrup Municipality, 2600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.